Blood Cancer Journal (Jun 2023)
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
- Jacobien R. Hilberink,
- Isabelle A. van Zeventer,
- Dana A. Chitu,
- Thomas Pabst,
- Saskia K. Klein,
- Georg Stussi,
- Laimonas Griskevicius,
- Peter J. M. Valk,
- Jacqueline Cloos,
- Arjan A. van de Loosdrecht,
- Dimitri Breems,
- Danielle van Lammeren-Venema,
- Rinske Boersma,
- Mojca Jongen-Lavrencic,
- Martin Fehr,
- Mels Hoogendoorn,
- Markus G. Manz,
- Maaike Söhne,
- Rien van Marwijk Kooy,
- Dries Deeren,
- Marjolein W. M. van der Poel,
- Marie Cecile Legdeur,
- Lidwine Tick,
- Yves Chalandon,
- Emanuele Ammatuna,
- Sabine Blum,
- Bob Löwenberg,
- Gert J. Ossenkoppele,
- Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON),
- Swiss Group for Clinical Cancer Research (SAKK),
- Gerwin Huls
Affiliations
- Jacobien R. Hilberink
- Department of Hematology, University Medical Center Groningen
- Isabelle A. van Zeventer
- Department of Hematology, University Medical Center Groningen
- Dana A. Chitu
- Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute
- Thomas Pabst
- Department of Oncology, University Hospital, Inselspital, and University of Bern
- Saskia K. Klein
- Department of Hematology, University Medical Center Groningen
- Georg Stussi
- Department of Hematology, Oncology Institute of Southern Switzerland, Ospedale Regionale
- Laimonas Griskevicius
- Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University
- Peter J. M. Valk
- Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute
- Jacqueline Cloos
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam
- Arjan A. van de Loosdrecht
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam
- Dimitri Breems
- Department of Hematology, ZNA Stuivenberg/Middelheim
- Danielle van Lammeren-Venema
- Department of Hematology, Hagaziekenhuis
- Rinske Boersma
- Department of Hematology, Amphia Hospital
- Mojca Jongen-Lavrencic
- Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute
- Martin Fehr
- Department of Medical oncology and Hematology, Kantonsspital St. Gallen
- Mels Hoogendoorn
- Department of Hematology, Medical Center Leeuwarden
- Markus G. Manz
- Department of Medical Oncology and Hematology, Universitätsspital Zurich
- Maaike Söhne
- Department of Hematology, Antonius Hospital
- Rien van Marwijk Kooy
- Department of Hematology, Isala Hospital
- Dries Deeren
- Department of Hematology, AZ Delta Roeselare
- Marjolein W. M. van der Poel
- Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center
- Marie Cecile Legdeur
- Department of Hematology, Medical Spectrum Twente
- Lidwine Tick
- Department of hematology, Maxima Medical Center
- Yves Chalandon
- Division of hematology, University Hospital Genève and Faculty of Medicine, University of Genève
- Emanuele Ammatuna
- Department of Hematology, University Medical Center Groningen
- Sabine Blum
- Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV)
- Bob Löwenberg
- Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute
- Gert J. Ossenkoppele
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam
- Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
- Swiss Group for Clinical Cancer Research (SAKK)
- Gerwin Huls
- Department of Hematology, University Medical Center Groningen
- DOI
- https://doi.org/10.1038/s41408-023-00850-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 9
Abstract
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.
